A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis
Clostridioides difficile infection (CDI) is a common cause of antimicrobial-associated diarrhea. Probiotics have shown variable results in decreasing its incidence and severity. We examined the efficacy of Lactobacillus reuteri administered using a novel probiotic biofilm delivery system in the trea...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-11-01
|
Series: | Gut Microbes |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/19490976.2020.1814119 |
id |
doaj-5b1c648885f44f94a5e67e10be033c35 |
---|---|
record_format |
Article |
spelling |
doaj-5b1c648885f44f94a5e67e10be033c352021-03-18T15:12:50ZengTaylor & Francis GroupGut Microbes1949-09761949-09842020-11-0112110.1080/19490976.2020.18141191814119A novel probiotic therapeutic in a murine model of Clostridioides difficile colitisRita D. Shelby0Grace E. Janzow1Lauren Mashburn-Warren2Jeffrey Galley3Natalie Tengberg4Jason Navarro5Miriam Conces6Michael T. Bailey7Steven D. Goodman8Gail E. Besner9Nationwide Children’s HospitalNationwide Children’s HospitalThe Research Institute at Nationwide Children’s HospitalNationwide Children’s HospitalNationwide Children’s HospitalNationwide Children’s HospitalNationwide Children’s HospitalThe Research Institute at Nationwide Children’s HospitalThe Research Institute at Nationwide Children’s HospitalNationwide Children’s HospitalClostridioides difficile infection (CDI) is a common cause of antimicrobial-associated diarrhea. Probiotics have shown variable results in decreasing its incidence and severity. We examined the efficacy of Lactobacillus reuteri administered using a novel probiotic biofilm delivery system in the treatment and prevention of CDI in a murine model. For prophylactic therapy, mice received an oral antibiotic cocktail followed by clindamycin injection, followed by probiotic administration (planktonic vs. biofilm state), followed by C. difficile oral gavage. For treatment therapy, mice received antibiotics and C. difficile first, followed by probiotic administration. Clinical sickness scores (CSS) and intestinal histologic injury scores (HIS) were assigned. In the Prophylactic Therapy model, CSS: 67% of untreated mice exposed to C. difficile demonstrated CSS ≥ 6, which is consistent with C. difficile infection (p< .001 compared to unexposed mice). In mice treated with planktonic Lr, 55% had a CSS ≥ 6, but only 19% of mice treated with Lr in its biofilm state had CSS ≥ 6 (p< .001). Mice receiving Lr + DM-Maltose lost the least amount of weight compared to mice receiving saline (p = .004676) or to mice receiving Lr (p= .003185). HIS: 77% of untreated mice exposed to C. difficile had HIS scores ≥4, which is consistent with C. difficile infection. In mice treated with planktonic Lr, 62% had HIS ≥4, but only 19% of mice treated with Lr in its biofilm state had HIS ≥4. (p< .001). Additionally, mice treated with Lr in its biofilm state had better survival compared to untreated mice and to mice treated with planktonic Lr (p ≤ 0.05). Similar findings for weight loss, CSS, HIS and survival were obtained for Treatment Therapy. A single dose of Lactobacillus reuteri in its biofilm state reduces the severity and incidence of experimental C. difficile infection when administered as both prophylactic and treatment therapy.http://dx.doi.org/10.1080/19490976.2020.1814119c. difficileprobioticslactobacillus reuteribiofilmtherapeutic treatmentprophylactic treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rita D. Shelby Grace E. Janzow Lauren Mashburn-Warren Jeffrey Galley Natalie Tengberg Jason Navarro Miriam Conces Michael T. Bailey Steven D. Goodman Gail E. Besner |
spellingShingle |
Rita D. Shelby Grace E. Janzow Lauren Mashburn-Warren Jeffrey Galley Natalie Tengberg Jason Navarro Miriam Conces Michael T. Bailey Steven D. Goodman Gail E. Besner A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis Gut Microbes c. difficile probiotics lactobacillus reuteri biofilm therapeutic treatment prophylactic treatment |
author_facet |
Rita D. Shelby Grace E. Janzow Lauren Mashburn-Warren Jeffrey Galley Natalie Tengberg Jason Navarro Miriam Conces Michael T. Bailey Steven D. Goodman Gail E. Besner |
author_sort |
Rita D. Shelby |
title |
A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis |
title_short |
A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis |
title_full |
A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis |
title_fullStr |
A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis |
title_full_unstemmed |
A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis |
title_sort |
novel probiotic therapeutic in a murine model of clostridioides difficile colitis |
publisher |
Taylor & Francis Group |
series |
Gut Microbes |
issn |
1949-0976 1949-0984 |
publishDate |
2020-11-01 |
description |
Clostridioides difficile infection (CDI) is a common cause of antimicrobial-associated diarrhea. Probiotics have shown variable results in decreasing its incidence and severity. We examined the efficacy of Lactobacillus reuteri administered using a novel probiotic biofilm delivery system in the treatment and prevention of CDI in a murine model. For prophylactic therapy, mice received an oral antibiotic cocktail followed by clindamycin injection, followed by probiotic administration (planktonic vs. biofilm state), followed by C. difficile oral gavage. For treatment therapy, mice received antibiotics and C. difficile first, followed by probiotic administration. Clinical sickness scores (CSS) and intestinal histologic injury scores (HIS) were assigned. In the Prophylactic Therapy model, CSS: 67% of untreated mice exposed to C. difficile demonstrated CSS ≥ 6, which is consistent with C. difficile infection (p< .001 compared to unexposed mice). In mice treated with planktonic Lr, 55% had a CSS ≥ 6, but only 19% of mice treated with Lr in its biofilm state had CSS ≥ 6 (p< .001). Mice receiving Lr + DM-Maltose lost the least amount of weight compared to mice receiving saline (p = .004676) or to mice receiving Lr (p= .003185). HIS: 77% of untreated mice exposed to C. difficile had HIS scores ≥4, which is consistent with C. difficile infection. In mice treated with planktonic Lr, 62% had HIS ≥4, but only 19% of mice treated with Lr in its biofilm state had HIS ≥4. (p< .001). Additionally, mice treated with Lr in its biofilm state had better survival compared to untreated mice and to mice treated with planktonic Lr (p ≤ 0.05). Similar findings for weight loss, CSS, HIS and survival were obtained for Treatment Therapy. A single dose of Lactobacillus reuteri in its biofilm state reduces the severity and incidence of experimental C. difficile infection when administered as both prophylactic and treatment therapy. |
topic |
c. difficile probiotics lactobacillus reuteri biofilm therapeutic treatment prophylactic treatment |
url |
http://dx.doi.org/10.1080/19490976.2020.1814119 |
work_keys_str_mv |
AT ritadshelby anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT graceejanzow anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT laurenmashburnwarren anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT jeffreygalley anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT natalietengberg anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT jasonnavarro anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT miriamconces anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT michaeltbailey anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT stevendgoodman anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT gailebesner anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT ritadshelby novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT graceejanzow novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT laurenmashburnwarren novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT jeffreygalley novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT natalietengberg novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT jasonnavarro novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT miriamconces novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT michaeltbailey novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT stevendgoodman novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis AT gailebesner novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis |
_version_ |
1724215679646695424 |